(1S,2S)-Bortezomib |
| カタログ番号GC62193 |
(1S,2S)-ボルテゾミブは、ボルテゾミブのエナンチオマーです。ボルテゾミブは、細胞透過性、可逆性、および選択的なプロテアソーム阻害剤であり、スレオニン残基を標的とすることにより、20S プロテアソーム (Ki 0.6 nM) を強力に阻害します。ボルテゾミブは細胞周期を乱し、アポトーシスを誘導し、NF-κB を阻害します。ボルテゾミブは抗がん剤であり、ヒトで使用される最初の治療用プロテアソーム阻害剤です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1132709-14-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
(1S,2S)-Bortezomib is an enantiomer of Bortezomib. Bortezomib is a cell-permeable, reversible, and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki of 0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is an anti-cancer agent and the first therapeutic proteasome inhibitor to be used in humans[1][2][3].
[1]. Kamalzadeh Z, et al. Determination of Bortezomib in API Samples Using HPLC: Assessment of Enantiomeric and Diastereomeric Impurities. J Chromatogr Sci. 2017 Aug 1;55(7):697-705.
[2]. Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22.
[3]. Shahshahan MA, et al. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastaticmelanoma: basic and clinical aspects. Am J Cancer Res. 2011;1(7):913-24.
Average Rating: 5 (Based on Reviews and 11 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *